New prognostic model for liver transplantation outcomes in hepatocellular carcinoma

Background. Liver transplantation remains a priority treatment option for hepatocellular carcinoma in the presence of liver cirrhosis; yet precise outcome prediction post-operation continues to be a complex challenge. Existing prognostic model often overlook patient age and donor type. Enhanced models that incorporate these parameters can improve prediction accuracy and treatment efficacy, which is critically important in the dynamically evolving field of transplantation.

Objective. The aim of this study is to develop a prognostic model for liver transplantation outcomes in patients with hepatocellular carcinoma and liver cirrhosis.

Material and methods. This retrospective study included 69 patients with hepatocellular carcinoma on the background of liver cirrhosis who underwent liver transplantation between May 2010 and December 2022. Of these, 42 patients (61%) received organs from living donors, and 27 (39%) from deceased donors. The study involved analysis of alpha-fetoprotein levels in blood, as well as assessment of radiological (maximum tumor nodule size, number of nodules) and histological parameters (maximum tumor nodule size, number of nodules, presence of vascular invasion). Cox regression model was used to predict recurrence-free survival, and the results for five-year recurrence-free survival, recipient age, and donor type were reused in the Cox model to predict overall survival.

Results. Four models for predicting recurrence-free survival and overall survival based on histological and radiological data were developed, demonstrating high prognostic value with C-indexes on training/test data of 0.76/1; 0.73/1; 0.78/0.8; 0.6/0.8 respectively. All models showed recurrence-free survival prediction accuracy comparable to the Milan criteria. The model outcomes are available as a calculator on the website https://nadit.ru/calculate_HCC.

Conclusion. The developed prognostic models are vital tools for personalized outcome prediction after liver transplantation for hepatocellular carcinoma. To enhance the accuracy of these models, further amalgamation and validation of data from various medical centers, as well as open scientific collaboration, are necessary.

1. Kim SJ, Kim JM. Prediction models of hepatocellular carcinoma recurrence after liver transplantation: a comprehensive review. Clin Mol Hepatol. 2022;28(4):739–753. PMID: 35468711 https://doi.org/10.3350/cmh.2022.0060

2. Granov AM, Granov DA, Zherebtsov FK, Gerasimova OA, Borovik VV, Osovskikh VV, et al. Liver transplantation. A single center experience of 100 cases. Russian Journal of Transplantology and Artificial Organs. 2012;14(4):11–16. (In Russ.). https://doi.org/10.15825/1995-1191-2012-4-11-16

3. Voskanyan SE, Sushkov AI, Artemyev AI, Zabezhinsky DA, Naydenov EV, Bashkov AN, et al. Salvage liver transplantation for hepatocellular carcinoma treatment. Pirogov Journal of Surgery. 2019;(10):21–28. (In Russ.). https://doi.org/10.17116/hirurgia201910121

4. Voskanyan SE, Naydenov EV, Artemyev AI, Kolychev IY, Zabezhinsky DA, Gubarev KK, et al. Long-term results of liver transplantation for hepatocellular carcinoma. Annals of Surgical Hepatology. 2021;26(2):68–82. (In Russ.). https://doi.org/10.16931/10.16931/1995-5464.2021-2-68-82.5

5. Olisov OD, Novruzbekov MS, Gulyaev VA, Lutsyk KN. The role of calcineurin inhibitors in the progression of hepatocellular carcinoma after liver transplantation. Transplantologiya. The Russian Journal of Transplantation. 2022;14(3):292–300. (In Russ.). https://doi.org/10.23873/2074-0506-2022-14-3-292-3006

6. Goldberg D, Mantero A, Newcomb C, Delgado C, Forde KA, Kaplan DE, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol. 2021;74(6):1398–1406. PMID: 33453328 https://doi.org/10.1016/j.jhep.2020.12.021

7. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, Fan J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154(1):128– 139. PMID: 28989060 https://doi.org/10.1053/j.gastro.2017.09.025

8. Humar A, Ganesh S, Jorgensen D, Tevar A, Ganoza A, Molinari M, et al. Adult living donor versus deceased donor liver transplant (LDLT Versus DDLT) at a single center: time to change our paradigm for liver transplant. Ann Surg. 2019;270(3):444–451. PMID: 31305283 https://doi.org/10.1097/SLA.0000000000003463

9. Goldaracena N, Gorgen A, Doyle A, Hansen BE, Tomiyama K, Zhang W, et al. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J Hepatol. 2019;70(4):666– 673. PMID: 30630009 https://doi.org/10.1016/j.jhep.2018.12.029

10. Beumer BR, Polak WG, De Man RA, Metselaar HJ, Van Klaveren D, Labrecque J, et al. Impact of waiting time on post-transplant survival for recipients with hepatocellular carcinoma: A natural experiment randomized by blood group. JHEP Rep. 2023;5(2):100629. PMID: 36654943 https://doi.org/10.1016/j.jhepr.2022.100629

11. Maspero M, Yilmaz S, Cazzaniga B, Raj R, Ali K, Mazzaferro V, et al. The role of ischaemia-reperfusion injury and liver regeneration in hepatic tumour recurrence. JHEP Rep. 2023; 5(11):100846. PMID: 37771368 https://doi.org/10.1016/j.jhepr.2023.100846

12. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4):986–994.e3. PMID: 22750200 https://doi.org/10.1053/j.gastro.2012.05.052

13. Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg. 2017;265(3):557–564. PMID: 27611615 https://doi.org/10.1097/SLA.0000000000001966

14. Mehta FY, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, et al. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3(4):493–500. PMID: 27838698 https://doi.org/10.1001/jamaoncol.2016.5116

15. Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016;263(5):842–850. PMID: 26779979 https://doi.org/10.1097/SLA.0000000000001578

16. Nam K, Lee J, Bae J, Chang Y, Cho Y, Sinn D, et al. Novel model to predict HCC recurrence after liver transplantation obtained using deep learning: a multicenter study. Cancers (Basel). 2020;12(10):2791. PMID: 33003306 https://doi.org/10.3390/cancers12102791